PriceTargets.com logo

NASDAQ:REPL - Replimune Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $55.13
  • Forecasted Upside: 70.03 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$32.42 As of 09/16/2021 04:03 PM ET
▲ +1.16 (3.71%)

This chart shows the closing price for REPL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Replimune Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REPL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REPL

Analyst Price Target is $55.13
▲ +70.03% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $55.13, with a high forecast of $67.00 and a low forecast of $48.00. The average price target represents a 70.03% upside from the last price of $32.42.

This chart shows the closing price for REPL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Replimune Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/18/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/23/2021SVB LeerinkLower Price TargetOutperform$55.00 ➝ $49.00High
8/9/2021HC WainwrightReiterated RatingBuy$60.00Low
8/9/2021SVB LeerinkLower Price TargetOutperform$56.00 ➝ $55.00Medium
2/5/2021HC WainwrightBoost Price TargetBuy$58.00 ➝ $60.00Medium
2/4/2021SVB LeerinkLower Price TargetOutperform$57.00 ➝ $56.00Medium
11/17/2020BTIG ResearchInitiated CoverageBuy$60.00High
11/10/2020HC WainwrightBoost Price TargetBuy$54.00 ➝ $58.00Low
11/6/2020BMO Capital MarketsBoost Price TargetOutperform$51.00 ➝ $57.00High
11/2/2020Jefferies Financial GroupInitiated CoverageBuy$67.00High
10/15/2020BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$40.00 ➝ $51.00High
10/15/2020BarclaysBoost Price TargetOverweight$29.00 ➝ $50.00High
10/15/2020HC WainwrightUpgradeNeutral ➝ Buy$25.00 ➝ $54.00High
10/15/2020SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $44.00High
10/14/2020Roth CapitalBoost Price TargetBuy$30.00 ➝ $50.00High
10/14/2020Chardan CapitalBoost Price TargetBuy$30.00 ➝ $48.00High
8/7/2020Chardan CapitalReiterated RatingBuy$30.00High
8/7/2020SVB LeerinkBoost Price TargetOutperform$25.00 ➝ $27.00Low
7/1/2020HC WainwrightReiterated RatingBuy ➝ Neutral$25.00High
6/4/2020BMO Capital MarketsBoost Price TargetOutperform$31.00 ➝ $40.00High
6/4/2020HC WainwrightReiterated RatingBuy$24.00 ➝ $25.00High
6/4/2020BarclaysBoost Price TargetOverweight$21.00 ➝ $25.00High
6/4/2020Chardan CapitalReiterated RatingBuy$29.00High
6/3/2020WedbushReiterated RatingOutperformMedium
5/4/2020BarclaysInitiated CoverageOverweight$21.00High
2/13/2020Chardan CapitalReiterated RatingBuy$28.00Low
1/21/2020HC WainwrightReiterated RatingBuy$26.00 ➝ $24.00High
11/20/2019WedbushLower Price TargetOutperform$30.00 ➝ $12.50Medium
11/11/2019Roth CapitalBoost Price TargetBuy$20.00 ➝ $30.00Low
10/24/2019Chardan CapitalReiterated RatingBuy$28.00Low
10/15/2019Chardan CapitalSet Price TargetBuy$28.00High
9/30/2019HC WainwrightReiterated RatingBuy$26.00Low
9/4/2019Roth CapitalInitiated CoverageBuy$20.00High
8/15/2019Chardan CapitalReiterated RatingBuy$28.00Medium
7/23/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$28.00Low
7/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$27.00 ➝ $26.00Low
7/8/2019HC WainwrightInitiated CoverageBuy ➝ Buy$26.00Low
4/24/2019WedbushInitiated CoverageOutperform ➝ Outperform$24.00High
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
8/14/2018SVB LeerinkInitiated CoverageOutperform$25.00Low
8/14/2018BMO Capital MarketsInitiated CoverageOutperform$31.00Low
8/14/2018JPMorgan Chase & Co.Initiated CoverageOverweight$26.00Low
(Data available from 9/16/2016 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2021

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Replimune Group logo
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Read More

Today's Range

Now: $32.42
Low: $31.43
High: $32.46

50 Day Range

MA: $32.29
Low: $28.98
High: $36.33

52 Week Range

Now: $32.42
Low: $20.40
High: $54.85

Volume

4,845 shs

Average Volume

337,612 shs

Market Capitalization

$1.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Replimune Group?

The following Wall Street research analysts have issued research reports on Replimune Group in the last twelve months: Barclays PLC, BMO Capital Markets, BTIG Research, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., Roth Capital, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for REPL.

What is the current price target for Replimune Group?

8 Wall Street analysts have set twelve-month price targets for Replimune Group in the last year. Their average twelve-month price target is $55.13, suggesting a possible upside of 70.0%. Jefferies Financial Group Inc. has the highest price target set, predicting REPL will reach $67.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $48.00 for Replimune Group in the next year.
View the latest price targets for REPL.

What is the current consensus analyst rating for Replimune Group?

Replimune Group currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe REPL will outperform the market and that investors should add to their positions of Replimune Group.
View the latest ratings for REPL.

What other companies compete with Replimune Group?

Other companies that are similar to Replimune Group include Halozyme Therapeutics, Adagio Therapeutics, Twist Bioscience, Adaptive Biotechnologies, Kodiak Sciences, Sana Biotechnology, Abcam, Editas Medicine, Recursion Pharmaceuticals, Ablynx, Iovance Biotherapeutics, SpringWorks Therapeutics, Allogene Therapeutics, Bavarian Nordic A/S and Relay Therapeutics.

How do I contact Replimune Group's investor relations team?

Replimune Group's physical mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company's listed phone number is (781) 222-9600 and its investor relations email address is [email protected] The official website for Replimune Group is www.replimune.com.